Who Should Avoid Lurbinectedin?
Lurbinectedin (Zepzelca) carries black box warnings for myelosuppression and hepatotoxicity, contraindicating use in patients with severe hypersensitivity to it or its components. Avoid in those with active or unresolved severe infection, or platelet count below 100,000/mm³ before starting.[1][2]
Precautions in Elderly Patients
Patients 65 and older face higher risks of fatal adverse events (54% vs. 33% in younger adults), severe myelosuppression, and renal impairment. Dose adjustments or monitoring may be needed, though no specific geriatric dosing exists.[1][3]
Liver and Kidney Impairment Guidelines
- Hepatic impairment: Prohibit use in severe cases (bilirubin >3x upper limit of normal or Child-Pugh C). Reduce dose by 25% for moderate (Child-Pugh B) impairment; monitor liver enzymes every 3 weeks.[1][2]
- Renal impairment: No dose adjustment for mild-moderate (CrCl 30-89 mL/min), but data are limited for severe (CrCl <30 mL/min). Elderly or comorbid patients need closer renal monitoring.[1]
Pregnancy, Breastfeeding, and Fertility Risks
Embryofetal toxicity is a black box warning—lurbinectedin can cause fetal harm. Verify pregnancy status before starting, use effective contraception during treatment and for 6 months after (women) or 4 months (men). Advise against breastfeeding during treatment and for 2 weeks after. May impair male fertility.[1][2]
Drug Interactions to Watch
CYP3A inducers (e.g., rifampin) reduce exposure—inhibit or avoid during treatment and for 5 days after. Strong CYP3A inhibitors (e.g., ketoconazole) increase exposure; monitor for toxicity. Live vaccines are contraindicated due to immunosuppression risk.[1]
Monitoring During Treatment
Require complete blood counts weekly for cycle 1, then before each cycle; delay or reduce dose for grade 3/4 neutropenia, thrombocytopenia, or anemia. Check liver function tests before each cycle and as clinically indicated.[1][2]
Sources
[1]: Zepzelca (lurbinectedin) Prescribing Information, Jazz Pharmaceuticals, 2023. https://www.zepzelca.com/
[2]: FDA Label for Zepzelca. https://www.accessdata.fda.gov/drugsatfdadocs/label/2020/213069s000lbl.pdf
[3]: Clinical Pharmacology Review, FDA Approval Package. https://www.accessdata.fda.gov/drugsatfdadocs/nda/2020/213069Orig1s000ClinPharmR.pdf